The significance of HER-2/neu receptor positivity and immunophenotype in ductal carcinoma in situ with early invasive disease

Journal of Surgical Oncology

Volumn 104, Issue 5, 2011, Pages 458-465

  Harada, Shuko ^a,d   Mick, Rosemarie ^b   Roses, Robert E ^b   Graves, Holly ^b   Niu, Huilin ^c   Sharma, Anupama ^b   Schueller, Jeanne E ^b   Nisenbaum, Harvey ^b   Czerniecki, Brian J ^b   Zhang, Paul J ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Guangzhou Children's Hospital   (China)

^d DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

breast cancer; ductal carcinoma in situ (DCIS); HER2; immunohistochemistry; invasive disease

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST BIOPSY; CANCER INVASION; CANCER SURGERY; FEMALE; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MALE; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPHENOTYPING; MIDDLE AGED; NEOPLASM INVASIVENESS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 80052483610     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21973     Document Type: Article

References (23)

1. Valenzuela M, Julian TB,: Ductal carcinoma in situ: Biology, diagnosis, and new therapies. Clin Breast Cancer 2007; 7: 676-681. (Pubitemid 47344729)
2. Allegra CJ, Aberle DR, Ganschow P, et al.: National Institutes of Health State-of-the-Science Conference statement: Diagnosis and management of ductal carcinoma in situ September 22-24, 2009. Natl Cancer Inst 2010; 102: 161-169.
3. Page DL, Dupont WD, Rogers LW, et al.: Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer 1995; 76: 1197-2000.
4. Perou CM, SÃrlie T, Eisen MB, et al.: Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
5. Perou CM, Jeffrey SS, van de Rijn M, et al.: Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA 1999; 96: 9212-9217. (Pubitemid 29374734)
6. Makretsov NA, Huntsman DG, Nielsen TO, et al.: Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006; 355: 560-569.
7. Sorlie T, Tibshirani R, Parker J, et al.: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418-8423. (Pubitemid 36842560)
8. Makretsov NA, Huntsman DG, Nielsen TO, et al.: Hierarchial clustering analysis of tissue microarray immunostaining data identifies prognostically significant group of breast carcinoma. Clin Cancer Res 2004; 10: 6143-6151. (Pubitemid 39287520)
9. Meijnen P, Peterse JL, Antonini N, et al.: Immunohistochemical categorisation of ductal carcinoma in situ of the breast. Br J Cancer 2008; 98: 137-142.
10. Tamimi RM, Baer HJ, Marotti J, et al.: Comparison of molecular phenotype of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res 2008; 10: R67.
11. Roses RE, Paulson EC, Sharma A, et al.: HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer. Cancer Epidemiol Biomarkers Prev 2009; 18: OF1-OF4.
12. Liao N, Zhang GC, Liu YH, et al.: HER2-positive status is an independent predictor for coexisting invasion of ductal carcinoma in situ of the breast presenting extensive DCIS component. Pathol Res Pract 2011; 207: 1-7.
13. Czerniecki BJ, Koski GK, Koldovsky U, et al.: Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res 2007; 67: 1842-1852. (Pubitemid 46383411)
14. Harvey JM, Clark GM, Osborne CK, et al.: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474-1481. (Pubitemid 29220854)
15. Wolff AC, Hammond ME, Schwartz JN, et al.: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. American Society of Clinical Oncology; College of American Pathologists. J Clin Oncol 2007; 25: 118-145. (Pubitemid 350003059)
16. Lester SC, Connolly JL, Amin MB,: College of American Pathologists protocol for the reporting of ductal carcinoma in situ. Arch Pathol Lab Med 2009; 133: 13-14.
17. Horimoto Y, Tokuda E, Arakawa A, et al.: Significance of HER2 protein examination in ductal carcinoma in situ. J Surg Res 2011; 167: e205-210.
18. Hoorntje LE, Schipper ME, Peeters PH, et al.: The finding of invasive cancer after a preoperative diagnosis of ductal carcinoma-in-situ: Causes of ductal carcinoma-in-situ underestimates with stereotactic 14-gauge needle biopsy. Ann Surg Oncol 2003; 10: 748-753. (Pubitemid 40486874)
19. Camp RL, Dolled-Filhart M, King BL, et al.: Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. Cancer Res 2003; 63: 1445-1448. (Pubitemid 36373626)
20. Gilcrease MZ, Woodward WA, Nicolas MM, et al.: Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer. Am J Surg Pathol 2009; 33: 759-767.
21. Park K, Han S, Kim HJ, et al.: HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemicstry. Histopathology 2006; 48: 702-707.
22. Boughey JC, Gonzalez RJ, Bonner E, et al.: Current treatment and clinical trial developments for ductal carcinoma in situ of the breast. Oncologist 2007; 12: 1276-1287. (Pubitemid 350232601)
23. Gonzalez RJ, Buzdar AU, Fraser Symmans W, et al.: Novel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastuzumab (Herceptin). Breast J 2007; 13: 72-75. (Pubitemid 46046497)